292 related articles for article (PubMed ID: 27896639)
1. SEOM Clinical Guideline for bone metastases from solid tumours (2016).
Grávalos C; Rodríguez C; Sabino A; Seguí MÁ; Virizuela JA; Carmona A; Cassinello J; Isla D; Jara C; Martín M
Clin Transl Oncol; 2016 Dec; 18(12):1243-1253. PubMed ID: 27896639
[TBL] [Abstract][Full Text] [Related]
2. SEOM guidelines for the treatment of bone metastases from solid tumours.
Cassinello Espinosa J; González Del Alba Baamonde A; Rivera Herrero F; Holgado Martín E;
Clin Transl Oncol; 2012 Jul; 14(7):505-11. PubMed ID: 22721794
[TBL] [Abstract][Full Text] [Related]
3. Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer.
Brodowicz T; Hadji P; Niepel D; Diel I
Cancer Treat Rev; 2017 Dec; 61():23-34. PubMed ID: 29100167
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
5. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
[TBL] [Abstract][Full Text] [Related]
6. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
7. Optimizing skeletal-related events prevention in patients with advanced prostate cancer.
Leung AK
Asia Pac J Clin Oncol; 2020 Sep; 16 Suppl 3():4-6. PubMed ID: 32852902
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
9. Bone-targeted agents in the treatment of lung cancer.
Silva SC; Wilson C; Woll PJ
Ther Adv Med Oncol; 2015 Jul; 7(4):219-28. PubMed ID: 26136853
[TBL] [Abstract][Full Text] [Related]
10. Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.
Miller K; Steger GG; Niepel D; Lüftner D
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):461-472. PubMed ID: 29988100
[TBL] [Abstract][Full Text] [Related]
11. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
[TBL] [Abstract][Full Text] [Related]
12. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
13. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
[TBL] [Abstract][Full Text] [Related]
14. Progress in the treatment of bone metastases in cancer patients.
Mackiewicz-Wysocka M; Pankowska M; Wysocki PJ
Expert Opin Investig Drugs; 2012 Jun; 21(6):785-95. PubMed ID: 22500564
[TBL] [Abstract][Full Text] [Related]
15. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
[TBL] [Abstract][Full Text] [Related]
17. [The treatment for cancer with bone metastases -whether to use zoledoronate or denosumab for bone metastases-].
Kohno N
Clin Calcium; 2014 Aug; 24(8):1229-36. PubMed ID: 25065876
[TBL] [Abstract][Full Text] [Related]
18. Management of bone metastases in patients with castration-resistant prostate cancer.
Cathomas R; Bajory Z; Bouzid M; El Ghoneimy A; Gillessen S; Goncalves F; Kacso G; Kramer G; Milecki P; Pacik D; Tantawy W; Lesniewski-Kmak K
Urol Int; 2014; 92(4):377-86. PubMed ID: 24802278
[TBL] [Abstract][Full Text] [Related]
19. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
Duran I; Fink MG; Bahl A; Hoefeler H; Mahmood A; Lüftner D; Ghazal H; Wei R; Chung KC; Hechmati G; Green J; Atchison C
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 26865392
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
